Galenica Investor Day: Updated mid-term guidance and strategy update

	Press release
	Ad hoc announcement pursuant to Art. 53 LR
Date	24 October 2023
Contact	Investor Relations: Felix Burkhard, CFO Galenica Group
	Media Relations: Christina Hertig, Head of Corporate Communications
Subject	Updated mid-term guidance
	Galenica Investor Day:
	Updated mid-term guidance and strategy update
	At today's Investor Day, Galenica is presenting its updated mid-term guidance. Galenica is
	raising its mid-term growth forecast and now expects annual net sales growth of between 3%
	and 5%. Furthermore, Galenica is confirming its mid-term targets for return on sales (ROS)1 at
	over 9.5% in the Products & Care segment and up to 2% in the Logistics & IT segment. At its
	Investor Day, Galenica will also provide in-depth insights into its strategic programmes and
	show how it intends to to tap into additional growth potential through innovation.
	Galenica is raising its mid-term growth forecast and now expects net sales to grow by 3% to 5% in
	the next years. To date, Galenica had expected sales to grow faster than the expected market
	growth of 1% to 2%.
	Galenica is confirming its mid-term targets for return on sales (ROS)1 at over 9.5% in the Products &
	Care segment and up to 2% in the Logistics & IT segment. Galenica aims to achieve these targets in
	its centenary year 2027 with an EBIT2 of over CHF 250 million. Due to an intensive final phase of the
	ERP project in the Logistics & IT segment, scheduled to be completed in 2025, ongoing
	investments in the digital Omni-Channel infrastructure as well as further investments in staff as a
	basis for the Group's successful further development, Galenica expects a stable development of its
	return on sales (ROS)1 up to 2025.
	Galenica assumes that the level of investments3 will remain stable over the next years and continues
	to aim for net debt2 of around +/-2× EBITDA2. Galenica continues to pursue a policy of at least
	stable dividends that grow in line with results.
	The current guidance for the 2023 financial year, with sales growth of between 3% and 6% and
	EBIT2 at roughly prior year level (based on the restated figures from the previous year) remains
	unchanged.
	Innovation as a driver of growth
	At today's Investor Day in Zurich, the Executive Committee will provide in-depth insights into
	current business activities and specific measures for implementing the strategic programmes under
	the umbrella of innovation. These include the further development of the Omni-Channel strategy,
	e.g. by connecting online and offline channels, the relevance of services in pharmacies and at
	home, and the introduction and development of digital medication solutions. Another focus is on
	the sustainable development of pharmaceutical logistics, which includes ensuring patient safety
	and security of supply in Switzerland.
	The presentations from Investor Day 2023 are available on the Galenica website. A recording will
	be available at galenica.com following the event.
	Galenica Investor Day will start at 9.30 a.m. (CEST) on 24 October 2023. Participate at the Investor
	Day online: Webcast
	Galenica Ltd.
	Untermattweg 8 | P.O. Box | CH-3001 Bern
	[phone] | [e-mail] | galenica.com
	Galenica - Health and well-being are at the heart of what we do.

Date	24 October 2023
Page	2/2
Subject	Updated mid-term guidance

1 ROS = EBIT adjusted (excluding the effect of IAS 19 and IFRS 16) / net sales, based on ROS 2023 excluding extraordinary factors 2 Adjusted (excluding the effect of IAS 19 and IFRS 16)

3 Investments in property, plant and equipment and intangible assets

Dates for the diary

18 January 2024: Publication of Galenica Group sales 2023

12 March 2024: Publication of Galenica Group annual results 2023

10 April 2024: Annual General Meeting of Galenica Ltd.

For further information, please contact:
Media Relations:	Investor Relations:
Christina Hertig, Head of Corporate Communications	Felix Burkhard, CFO
Tel. [phone]	Tel. [phone]
E-mail:[e-mail]	E-mail:[e-mail]

Welcome to the Galenica network!

Our ambition is to meet the needs of patients and customers in the Swiss healthcare market in a seamless, efficient and personalised way. To achieve this, we operate the Galenica network with over 20 Business Units, the strongest partners in the Swiss healthcare market. We offer fully integrated solutions both for customers and patients as well as for pharmacies, drugstores, medical practices, hospitals, retirement and nursing homes, home care providers, wholesalers, pharmaceutical companies, health insurance funds and other partners.

Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information concerning Galenica can be found at www.galenica.com.